Open Peer Review on Qeios

The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review (version 4)

David Simons¹, Lion Shahab², Jamie Brown², Olga Perski²

Royal Veterinary College, RVC
 University College London, University of London

Funding: The author(s) received no specific funding for this work.Potential competing interests: The author(s) declared that no potential competing interests exist.

Abstract

Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic disease which has reached pandemic levels and is designated a public health emergency of international concern. It is plausible that former or current smoking status is associated with infection, hospitalisation and/or mortality from COVID-19.

Objective: We aimed to estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.

Methods: This is a living evidence review with frequent updates. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract data and another verify. Published articles and pre-prints were identified via Ovid MEDLINE, medRxiv and expertise within the review team. We included observational or experimental studies with community-dwelling or hospitalised adults aged 16+ years who had received a test for SARS-CoV-2 infection or a diagnosis of COVID-19, providing that data on smoking status were reported. Studies were judged as 'good' quality if they: i) had low levels of missing data on smoking status (i.e. <20%) and used a reliable self-report measure that distinguished between current, former and never smoking status, ii) used biochemical verification of smoking status, and iii) adjusted smoking and COVID-19 analyses for covariates that are likely to confound these associations (e.g. age, non-smoking

related comorbidities).

Results: Version 4 with searches up to 3 June 2020 included 102 studies, 36 of which were conducted in China, 25 in the US, nine in the UK, six in Mexico, six in Spain, five in France, four in Italy, three across multiple international sites, two in Israel, and one each from Finland, Iran, Korea, Kuwait, Saudi Arabia and Switzerland. Twenty-one (20.6%) studies reported current, former and never smoking status. Twenty-seven studies explicitly reported the proportion missing data on smoking status, which ranged from 0.08% to 96.3%. Notwithstanding recording uncertainties, compared with adult national prevalence estimates, recorded current and former smoking rates were generally lower than expected, but similar to expected in studies conducted in the UK. In seven 'fair' quality studies, current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.73, 95% CI = 0.54-0.99, p = .046, I2 = 93%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.88-1.18, p = .80, I2 = 84%). In five 'fair' quality studies, there was no significant difference between current and never (RR = 1.12, 95% CI = 0.74-1.69, p = .48, I2 = 84%) or former and never smokers (RR = 1.21, 95% CI = 0.82-1.79, p = .24, I2 = 81%) in the risk of requiring admission to hospital with COVID-19 among those testing positive in the community. In four 'fair' quality studies, current smokers admitted to hospital were at increased risk of greater disease severity compared with never smokers (RR = 1.39, 95% CI = 1.09-1.77, p < .01, I2 = 0%). No significant difference was observed between former and never smokers (RR = 1.40, 95% CI = 0.76-2.59, p = .28, I2 = 74%). In two 'fair' quality studies, there was no significant difference between current and never (RR = 1.41, 95% CI = 0.91-2.20, p = .12, I2 = 40%) or former and never smokers (RR = 0.98, 95% CI = 0.65-1.48, p = .93, I2 = 0%) in the risk of in-hospital mortality from COVID-19.

Conclusions: Across 102 studies, there is substantial uncertainty about the associations of smoking with COVID-19 outcomes. The recorded smoking prevalence in the included studies was generally lower than overall adult national estimates. There was no evidence of reduced risk of admission to hospital in current compared with never smokers among those testing positive in the community from five 'fair' quality studies. There was some evidence from 'fair' quality studies that current compared with never smoking is associated with reduced risk of testing positive in the community but greater disease severity in those hospitalised for COVID-19.

Implications: Unrelated to COVID-19, smokers are at a greater risk of a range of

serious health problems. Given uncertainty around the association of smoking with COVID-19 outcomes, smoking cessation remains a public health priority and highquality smoking cessation advice including recommendations to use alternative nicotine products should form part of public health efforts during this pandemic. High quality, smoking-specific research is needed to resolve these mixed findings.

Introduction

COVID-19 is a respiratory disease caused by the emerging SARS-CoV-2 virus. Large age and gender differences in case severity and mortality have been observed in the ongoing COVID-19 pandemic¹; however, these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the ACE-2 receptor². Some evidence suggests that gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers^{3,4}, thus putting smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest that nicotine downregulates the ACE-2 receptor⁵. These uncertainties notwithstanding, both former and current smoking is known to increase the risk of respiratory viral^{6,7} and bacterial^{8,9} infections and is associated with worse outcomes once infected. Cigarette smoke reduces the respiratory immune defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and disruption of the respiratory epithelium¹⁰. There is also reason to believe that behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection and transmission in current smokers. However, early data from the COVID-19 pandemic have not provided clear evidence for a negative impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes, such as hospitalisation or mortality¹¹. It has also been hypothesised that nicotine might protect against a hyper-inflammatory response (or "cytokine storm") to SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19 disease^{12.}

There are several reviews that fall within the scope of smoking and COVID-19^{11,13–17}. We aimed to produce a rapid synthesis of available evidence pertaining to the rates of infection, hospitalisation, disease severity and mortality from SARS-CoV-2/COVID-19 stratified by smoking status. Given the increasing availability of data on this topic, this is a living review with regular updates. As evidence accumulates, the review will be expanded to include studies reporting COVID-19 outcomes by alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes).

Methods

Study design

This is a living evidence review which is updated as new evidence becomes available¹⁸. We adopted recommended practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract the data and another verify¹⁹.

Eligibility criteria

Studies were included if they:

 Were primary research studies using experimental (e.g. randomised controlled trial), quasi-experimental (e.g. pre- and post-test) or observational (e.g. case-control, retrospective cohort, prospective cohort) study designs;

2) Included adults aged 16+ years;

3) Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody assays), ii) clinical diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity of COVID-19 disease in those hospitalised or v) mortality from COVID-19;

4) Reported any of the outcomes of interest by self-reported or biochemically verified smoking status (e.g. current smoker, former smoker, never smoker);

5) Were available in English;

6) Were published in a peer-reviewed journal, as a pre-print or a public health report by reputable agents (e.g. governments, scientific societies).

Search strategy

The following terms were searched for in Ovid MEDLINE as free text or Medical Subject Headings:

1) Tobacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or Smoking Pipes/ or Cigar Smoking/ or Smoking Prevention/ or Cigarette Smoking/ or smoking.mp. or Pipe Smoking/ or Smoking, Non-Tobacco Products/ or Smoking Water Pipes/

2) Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing Gum/ 3) vaping.mp. or Vaping/
4) 1 or 2 or 3
5) Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or covid.mp.
6) 4 and 5

The following terms were searched for in titles, abstracts and full texts in medRxiv:

- 1) covid smoking
- 2) covid nicotine
- 3) covid vaping

Additional articles/reports of interest were identified through mailing lists, T witter, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), the Intensive Care National Audit & Research Centre (ICNARC) and the US Centers for Disease Control and Prevention (CDC).

Where updated versions of pre-prints or public health reports were available, old versions were superseded.

Selection of studies

One reviewer screened titles, abstracts and full texts against the inclusion criteria.

Data extraction

Data were extracted by one reviewer and verified by a second on i) author (year); ii) date published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix) smoking status (e.g. current, former, never, not stated, missing); x) SARS-CoV-2 infection; xi) diagnosis of COVID-19; xii) hospitalisation with COVID-19; xiii) disease severity in those hospitalised with COVID-19; and xiv) mortality.

Quality appraisal

In previous review versions, we used the National Institutes of Health's Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies to determine the quality of included studies²⁰. However, we decided against applying the entire tool in the Q

current review version. The appraisal is challenging to apply when studying an emerging disease with unknown pathology. For example, it is not possible to determine what proportion of eligible participants/patients are included in the studied populations when the total number of infections in a given region/city is unknown. With a largely unknown disease process, it is also difficult to determine whether the time between the exposure and outcome is sufficient. We therefore focused on three of the 14 criteria to determine whether studies were of sufficient quality to warrant inclusion in meta-analysis. Studies were judged as 'good' quality if they: i) had low levels of missing data on smoking status (i.e. <20%) and used a reliable self-report measure that distinguished between current, former and never smoking status, ii) used biochemical verification of smoking status, and iii) adjusted smoking and COVID-19 analyses for covariates that are likely to confound these associations (e.g. age, non-smoking related comorbidities). Studies were rated as 'fair' if they fulfilled criterion i) and were otherwise rated as 'poor'. The quality appraisal was conducted by one reviewer and verified by a second.


Evidence synthesis

A narrative synthesis was conducted. Where possible, data were pooled in R v.3.6.3²¹ with the Mantel-Haenszel or inverse variance method using random or fixed effects, depending on heterogeneity, and presented as risk ratios (RRs)²². Heterogeneity between study outcomes was assessed using the I² statistic, suitable for smaller meta-analyses²³.

To aid in the visualisation of smoking prevalence in the included studies, 95% bootstrap percentile confidence intervals were calculated. We performed 1,000 bootstrap replications, with the 2.5th and 97.5th percentiles of the empirical distribution forming the 95% bootstrap percentile confidence intervals²⁴. Prevalence estimates in the included studies were not adjusted for age, sex or socioeconomic position.

Results

In the current review version (v4), a total of 456 new records were identified, with 102 studies included in a narrative synthesis and 16 studies included in meta-analyses (see Figure 1).



Study characteristics

Characteristics of included studies are presented in Table 1. Thirty-six studies were conducted in China, 25 in the US, nine in the UK, six in Mexico, six in Spain, five in France, four in Italy, three across multiple international sites, two in Israel, and one each in Finland, Iran, Korea, Kuwait, Saudi Arabia and Switzerland. Eighty-one studies were conducted in hospital settings. Sixteen studies included a community component in addition to hospitalised patients. Three studies were conducted in the community, one in a quarantine centre and one did not state the study setting. Studies had a median of 310 (interquartile range = 95-1,006) participants.

Smoking status

Categorisation of smoking status was heterogeneous (see Table 1). Sixty-two studies collected data on smoking status through routine electronic health records, 25 studies used a bespoke case report form for COVID-19 and 15 studies did not state the source for information on smoking status. None of the studies verified smoking status biochemically. Notably, only 22 (21.6%) studies reported current, former and never smoking status, with a further seven studies reporting current/former and never smoking status. The remaining 73 studies reported current, current/former or current

and former smoking status but did not explicitly state whether remaining participants were never smokers or if data were missing on smoking status. Twenty-seven studies explicitly reported the proportion missing data on smoking status, which ranged from 0.08% to 96.3%. One study²⁵ reported that 91.4% of former smokers had been quit \geq 6 months prior to COVID-19 disease onset; the remaining studies did not report time since quitting in former smokers.

Use of alternative nicotine products

Two studies recorded the use of alternative nicotine products in current and/or former smokers but did not report COVID-19 outcomes stratified by nicotine use.

Quality appraisal

Nineteen studies were rated as 'fair' quality due to having low levels of missing data and distinguishing between current, former and never smoking status (see Appendix 1). The remaining 83 studies were rated as 'poor' quality.

Reference	Lead author	Date published	Countr y	Sample size	Study setting	Median age (IQR)	Female %	Current smokers %	Current/former smokers %	Never smokers %	Never/unknow n smokers %	Missing %	Overall rating (poor, fair, good)
[1]	Guan, Ni	2020-02-28	China	1,099	Hospital	47 (35-58)	41.90	12.47	-	84.35	-	1.27	Fair
[26]	Guan, Liang	2020-03-26	China	1,590	Hospital	49 (33-64)	42.70	-	6.98	93.02	-	0.00	Poor
[27]	Lian	2020-03-25	China	788	Hospital	-	38.50	6.85	-	-	-	93.15	Poor
[28]	Jin	2020-03-24	China	651	Hospital	46 (32-60)	49.20	6.30	-	-	-	93.70	Poor
[29]	Chen	2020-03-26	China	548	Hospital	62 (44-70)	37.60	4.38	-	-	-	93.07	Poor
[30]	Zhou, Yu	2020-03-11	China	191	Hospital	56 (46-67)	38.00	5.76	-	-	-	94.24	Poor
[31]	Mo	2020-03-16	China	155	Hospital	54 (53-66)	44.50	3.87	-	-	-	96.13	Poor
[32]	Zhang, Dong	2020-02-19	China	140	Hospital	57^ (25-87)	46.30	1.43	-	-	-	93.57	Poor
[33]	Wan	2020-03-21	China	135	Hospital	47 (36-55)	46.70	6.67	-	-	-	93.33	Poor
[34]	Liu, Tao	2020-02-28	China	78	Hospital	38 (33-57)	50.00	-	6.41	-	-	93.59	Poor
[35]	Huang, Wang	2020-01-24	China	41	Hospital	49 (41-58)	27.00	7.32	-	-	-	92.68	Poor
[36]	Zhang, Cai	2020-03-20	China	645	Hospital	-	49.10	6.36	-	-	-	93.64	Poor
[37]	Guo	2020-03-27	China	187	Hospital	59 (45-73)	51.30	9.63	-	-	-	90.37	Poor
[38]	Liu, Ming	2020-03-12	China	41	Hospital	39 (30-48)	58.50	9.76	-	-	-	90.24	Poor
[35]	Huang, Yang	2020-03-05	China	36	Hospital	69 (60-78)	30.60	-	11.11	-	-	88.89	Poor
[39]	Xu	2020-03-08	China	53	Hospital	-	47.20	11.32	-	-	-	88.68	Poor

Table 1. Characteristics of included studies.

[40]	Li	2020-02-12	China	17	Hospital	45 (33-57)	47.10	17.65	-	-	-	82.35	Poor
[41]	Rentsch	2020-04-14	USA	3,528	Community and Hospital	66 (60-70)	4.60	27.18		36.92		5.30	Fair
[42]	Hu	2020-03-25	China	323	Hospital	61^ (23-91)	48.60	-	11.76	-	-	88.24	Poor
[43]	Wang, Pan	2020-03-24	China	125	Hospital	41 (26-66)	43.20	-	12.80	-	-	87.20	Poor
[44]	Petrilli	2020-04-11	USA	4,103	Community and Hospital	52 (36-65)	47.90	5.17	-	-	78.60	0.00	Poor
[45]	Chow (US CDC)	2020-03-31	USA	7,162	Community and Hospital	-	-	1.34	-	-	-	96.36	Poor
[46]	Dong, Cao	2020-03-20	China	9	Hospital	44 (30-46)	66.70	11.11	-	-	-	88.89	Poor
[47]	Kim	2020-04-01	Korea	28	Hospital	43 (30-56)	46.40	17.86	-	-	-	82.14	Poor
[48]	Shi, Yu	2020-03-18	China	487	Hospital	46 (27-65)	46.80	-	8.21	-	-	91.79	Poor
[49]	Yang, Yu	2020-02-24	China	52	Hospital	60 (47-73)	37.00	3.85	-		-	96.15	Poor
[⁵⁰]	Argenziano	2020-04-22	USA	1,000	Hospital	63 (50-75)	40.40	4.90	-	77.20	-	0.00	Fair
[51]	Solis	2020-04-25	Mexico	650	Hospital	46	42.10	9.38		-	-	90.62	Poor
[⁵²]	Richardson	2020-04-22	USA	5,700	Hospital	63 (52-75)	39.70	-	9.79	52.79	-	37.42	Poor
[53]	Fontanet	2020-04-23	France	661	Community and Hospital	37 (16-47)	62.00	10.44	-	-	89.56	0.00	Poor
[54]	Zheng, Gao	2020-04-19	China	66	Hospital	47^	25.80	12.12	-	-	-	87.88	Poor
[55]	Liao, Feng	2020-04-24	China	1,848	Hospital	55 (48-61)	54.70	-	0.43	-	-	99.57	Poor
[⁵⁶]	Rodriguez- Cola	2020-04-24	Spain	7	Hospital	68 (34-75)	28.60	-	42.86	57.14	-	0.00	Poor
[57]	Magagnoli	2020-04-16	USA	368	Hospital	69 (59-75)	0.00	-	14.13	-	-	85.87	Poor
						46							-
[58]	Shi, Ren	2020-04-23	China	134	Hospital	(34-58) 55	51.50	-	10.45	-	-	89.55	Poor
[59]	Hadjadj	2020-04-23	France	50	Hospital Community	(50-63)	22.00	2.00	-	80.00	-	0.00	Fair
[⁶⁰]	Niedzwiedz Gold (US	2020-04-30	UK	1,474	and Hospital		-	9.98	-	55.04	-	0.59	Fair
[61]	CDC)	2020-04-20	USA	305	Hospital	-	50.50	5.25	-	-	-	94.75	Poor
[62]	Yu, Cai	2020-04-27	China	95	Hospital	-	44.21	8.42	-	-	-	91.58	Poor
[63]	Zheng, Xiong	2020-04-30	China	73	Hospital	43^	45.20	-	10.96	89.04	-	0.00	Poor
[25]	Miyara	2020-05-09	France	479	Community and Hospital	-	44.70	6.68	-	59.71	-	1.88	Fair
[64]	de la Rica	2020-05-11	Spain	48	Hospital	66^ (33-88)	33.00	-	20.83	-	-	79.17	Poor
[65]	Yin, Yang	2020-05-10	China	106	Hospital	73 (61-85)	39.60	-	16.98	-	-	83.02	Poor
[66]	Gaibazzi	2020-05-10	Italy	441	Hospital	71 (62-80)	38.00	4.76	-	85.26	-	0.00	Fair
[67]	Shi, Zuo	2020-05-10	USA	96	Hospital	63^ (44-82)	41.00	-	30.21	-	-	69.79	Poor
[68]	Cho	2020-05-11	UK	1,331	Community and Hospital	-	49.20	19.01	-	54.02	-	0.00	Fair
[69]	Allenbach	2020-05-08	France	152	Hospital	77 (60-83)	31.10	-	6.58	-	-	93.42	Poor
[70]	Robilotti	2020-05-08	USA	423	Hospital		50.00	2.13	-	58.63		1.65	Fair
[71]	The Opensafely Collaborativ e	2020-05-07	UK	17,425,445	Community and Hospital		50.10	17.00	-	45.91	-	4.16	Fair
[72]	Borobia	2020-05-06	Spain	2,226	Hospital	61 (46-78)	52.00	7.05	-	-	-	92.95	Poor
[73]	Giacomelli	2020-05-06	Italy	233	Hospital	61 (50-72)	31.90	-	30.04	69.96	-	0.00	Poor

[74]	Shah	2020-05-06	USA 31	6 Hospital	63 (43-72)	48.10	16.46	-	42.09	-	23.73	Poor
[75]	Bello- Chavolla	2020-05-06	Mexico 62,48	Community 9 and Hospital	-	49.40	-	9.94	-	-	90.06	Poor
[76]	Kolin	2020-05-05	UK 1,47	Community 4 and Hospital	58 (49-67)	46.60	14.45	-	44.57		0.81	Fair
["]	Lubetzky	2020-05-08	USA 5	4 Hospital	57 (29-83)	62.00	-	22.22	-	-	77.78	Poor
[78]	Goyal	2020-04-17	USA 39	3 Hospital	62.2 (49-74)	39.30	5.09	-	-	-	94.91	Poor
[²⁹]	Feng	2020-04-10	China 47	6 Hospital	53 (40-64)	43.10	9.24	-	-	-	90.76	Poor
[⁸⁰]	Yao	2020-04-24	China 10	8 Hospital	52 (37-58)	60.20	3.70	-	-	-	96.30	Poor
[81]	Sami	2020-05-15	Iran 49	0 Hospital	56.6 (41-71)	39.00	14.08	-	-	85.92	0.00	Poor
[82]	Almazeedi	2020-05-15	Kuwait 1,09	6 Hospital	41 (25-57)	19.00	4.01	-	-	95.99	0.00	Poor
[83]	Carrillo- Vega	2020-05-14	Mexico 10,54	Community 4 and Hospital	46.5^ (30-62)	42.30	8.88	-	-	-	91.12	Poor
[84]	Yanover	2020-05-13	Israel 4,35	Community 3 and Hospital	35 (22-54)	44.50	11.81	-	85.23	-	0.00	Fair
[85]	Hamer	2020-05-13	UK 387,10	9 Hospital	56.2 (48-64)	55.10	9.67	-	55.50	-	0.00	Fair
[⁸⁶]	Regina	2020-05-14	Switzer 20 land	0 Hospital	70 (55-81)	40.00	4.50	-	-	-	95.50	Poor
[87]	de Lusignan	2020-05-15	UK 3,80	2 Community	58 (34-73)	57.60	10.86	-	29.59	-	13.44	Fair
[88]	Targher	2020-05-13	China 33	9 Hospital	48.4^ (NA)	52.80	8.26	-	-	-	91.74	Poor
[89]	Valenti	2020-05-18	Italy 78	9 Community	40.7^ (NA)	34.98	25.86	-	-	-	74.14	Poor
[ao]	Feuth	2020-05-18	Finland 2	8 Hospital	56 (47-72)	46.00	10.71	-	60.71	-	0.00	Fair
[91]	Ge	2020-05-18	China 51	Hospital	70	27.50	13.73	-	_	-	86.27	Poor
				Community	(58-79) 44.9							
[92]	Parrotta		USA 76	and Hospital	(13-71)	61.80	2.63	-	68.42	-	2.63	Fair
[93]	Shekhar		USA 50	Hospital	55.5 (20-85) 49	54.00	48.00	-	-	-	52.00	Poor
	Mejia-Vilet		Mexico 329	Hospital	49 (41-60)	36.00	-	6.99	-	-	93.01	Poor
	Chen, Jiang	2020-05-16	China 135	Hospital	-	42.20	-	9.63	-	-	90.37	Poor
	Li		China 1,008	Hospital	55 (44-65) 59	43.60	5.65	-	-	-	94.35	Poor
[97]	Rimland	2020-05-19	USA 11	Hospital	(48-65) 64	18.20	9.09	-	-	-	81.82	Poor
[36]	Palaiodimos	2020-05-15	USA 200	Hospital	(50- 73.5)	51.00	-	32.50	67.50	-	0.00	Poor
[99]	lp	2020-05-25	USA 2,512	Hospital	64 (52-76)	37.62	3.07	-	64.49	-	14.61	Fair
[100]	Heili-Frades	2020-05-25	Spain 4,712	Hospital	62 (47-77)	50.50	4.94		-	66.49	11.16	Poor
[101]	Vaquero- Roncero	2020-05-24	Spain 146	Hospital	66^ (59-72)	32.20	-	6.85	-	-	93.15	Poor
[102]	Kim, Garg	2020-05-22	USA 2,491	Hospital	62 (50-75)	46.80	6.02	-	-	68.13	0.08	Poor
[103]	Wu	2020-05-21	Italy 174	Hospital	61.2 [^] (50-71)	30.46	-	33.33	-		66.67	Poor
[104]	Shi, Zhao	2020-05-20	China 101	Hospital	71 (59-80)	40.60	-	4.95	-	-	95.05	Poor
[106]	Kimmig		USA 60		64 (50-68)	41.67	-	36.67	-	-	63.33	Poor
[106]	Al-Hindawi		UK 31	•	61 62	12.90 72.00	3.23	-	25.81	-	0.00 82.27	Fair
[107]	Basse Freites		France 141 Spain 123		(52-72) 59.88^	69.92	3.25	-	-	-	82.27 96.75	Poor
[108]	rreites	2020-05-19	Spain 123	Hospital	(44-74)	69.92	3.25	-	-	-	96.75	Poor

Alshami	2020-05-19	Saudi Arabia	128 Quarant Centre	ine 39.6 [^] (24-55)	53.90	15.62	-	-	-	82.03	Poor
Russell	2020-05-19	UK	106 Hospita	67^ (52-81)	45.30	6.60	-	39.62	-	29.25	Poor
Berumen	2020-05-26	Mexico 102,	875 Hospita	-	49.08	-	9.64	-	90.36	0.00	Poor
Gianfrances co	2020-05-29	Multiple	600 and	(AE 07)	71.00		21.50	64.83	-	13.67	Poor
Li, Long	2020-05-28	China	145 Not Stat	ed (13-80)	61.00	-	5.52	-	-	94.48	Poor
Batty	2020-06-01	UK	908 Hospital	57.27 [^] (48-66)	44.27	11.23	-		-	88.77	Poor
Israel	2020-06-01	Israel 24,	087 and	(24.62)	48.70	17.08	-	69.88	-	0.00	Fair
del Valle	2020-05-30	USA 1,4	484 Hospital	62 (52-72)	40.60	5.53	-	-	-	71.16	Poor
Zuo, Zuo	2020-05-29	USA	44 Hospital	57^ (45-69)	18.18	-	27.27	-	-	72.73	Poor
Chaudhry	2020-05-29	USA	40 and	(45.5-	60.00	-	15.00	-	-	85.00	Poor
Louis	2020-06-28	USA	22 Hospital	66.5 [^] (55-77)	36.40	-	45.45	-	-	54.55	Poor
Soto-Mota	2020-05-27	Mexico	400 Hospital		30.00	-	12.00	-	-	88.00	Poor
Patel	2020-05-26	USA	104 Hospital	60.66 [^] (47-74)	47.00	41.35	-	-	49.04	9.62	Poor
Garibaldi	2020-05-26	USA	832 Hospita	63 (49-75)	47.00	5.53	-	-	-	71.88	Poor
Docherty	2020-05-22	Multiple 20,	133 Hospita	72.9 (58-82)	40.00	4.23	-	44.54	-	29.55	Poor
Boulware	2020-03-06	Multiple	821 Commu	nity 40 (33-50)	51.60	3.29	-	-	-	96.71	NA
	Russell Berumen Gianfrances co Li, Long Batty Israel Israel Zuo, Zuo Chaudhry Louis Soto-Mota Patel Garibaldi	Russell 2020-05-19 Berumen 2020-05-26 Cianfrances 2020-05-29 Li, Long 2020-05-29 Baty 2020-06-11 Israel 2020-05-30 Calvarder 2020-05-30 Calvarder 2020-05-30 Zuo, Zuo 2020-05-29 Chaudhry 2020-05-27 Patel 2020-05-26 Garibaldi 2020-05-26 Garibaldi 2020-05-26 Docherty 2020-05-26	Assistantin 2020-03-19 Arabia Russell 2020-05-29 UK 102,1 Berumen 2020-05-26 Mexico 102,2 Gianfrances 2020-05-28 Multiple 102,2 Gianfrances 2020-05-28 China 102,2 Batty 2020-06-01 UK 102,2 Israel 2020-06-01 Israel 24,1 del Valle 2020-06-20 USA 1,2 Chaudhry 2020-05-29 USA 1,2 Louis 2020-05-29 USA 1,2 Louis 2020-05-29 USA 1,2 Chaudhry 2020-05-29 USA 1,2 Garibaldi 2020-05-26 USA 1,2 Garibaldi 2020-05-26 USA 1,2 Garibaldi 2020-05-26 USA 1,2	Asisanini 2020-05-19 Arabia 1.28 Centre Russell 2020-05-19 UK 106 Hospital Berumen 2020-05-26 Mexico 102,875 Hospital Gianfrances 2020-05-28 Muitiple 600 Commu Asspital Li, Long 2020-05-28 China 145 Not Stat Bathy 2020-05-29 UK 908 Hospital Israel 2020-05-01 UK 908 Hospital Israel 2020-05-29 USA 1.48 Hospital Zuo, Zuo 2020-05-29 USA 1.48 Hospital Chaudhry 2020-05-29 USA 4.0 Anoptal Louis 2020-05-29 USA 2.2 Hospital Soto-Mota 2020-05-29 USA 1.04 Hospital Garibadci 2020-05-26 USA 1.04 Hospital Garibadci 2020-05-26 USA 3.04 Hospital Garibadci 2020	Assnamm 2020-05-19 Arabia 12.5 Centre (24-55) Russell 2020-05-19 UK 106 Hospital 677 Berumen 2020-05-26 Mexico 102,875 Hospital 645-57 Gianfrances 2020-05-26 Mexico 102,875 Hospital 465-67 Li, Long 2020-05-28 China 145 Not Stated 490- (45-67) Batty 2020-06-01 UK 908 Hospital 424- (24-68) Israel 2020-06-01 UK 908 Hospital 62- (25-72) Zuo, Zuo 2020-05-20 USA 1,484 Hospital 62- (25-72) Zuo, Zuo 2020-05-29 USA 40 And Hospital 62- (25-72) Chaudhry 2020-05-29 USA 40 Hospital 65- 65- 70) Soto-Mota 2020-05-29 USA 40 Hospital 65- 65- 70) Soto-Mota 2020-05-26 USA 22 Hospital 66- 67- 67- 67- 70	Alshami 2020-05-19 Arabia 1.26 Centre (24-55) 53.90 Russell 2020-05-19 UK 106 Hospital 67 45.30 Berumen 2020-05-26 Mexico 102,875 Hospital 49.08 Gianfrances 2020-05-28 Multiple 600 Community Hospital 56 71.00 Li, Long 2020-05-28 China 145 Not Stated 49.49 61.00 Batty 2020-05-28 China 145 Not Stated 72.27 (48-66) 44.27 Israel 2020-06-01 UK 908 Hospital 52.72 (48-66) 48.70 (45.59) 18.18 Chaudhry 2020-05-29 USA 1.48 Hospital (52.72) 40.60 Zuo, Zuo 2020-05-29 USA 1.48 Hospital (55.77) 36.40 Chaudhry 2020-05-29 USA 22 Hospital (65.57) 36.40 Soto-Mota 2020-05-26 USA 104 Hosp	Assnami 2020-05-19 Arabia 1.6 Centre (24,55) 53.30 15.22 Russell 2020-05-19 UK 106 Hospital 67/ (52-81) 45.30 6.60 Berumen 2020-05-26 Mexico 102,875 Hospital - 49.08 - Gianfrances co 2020-05-28 Multiple 600 Community Arabia 55/ (45-67) 71.00 - Li, Long 2020-05-28 China 145 Not Stated 49/ (13-80) 61.00 - Batty 2020-05-28 China 145 Not Stated 49/ (13-80) 61.00 - Batty 2020-06-01 UK 908 Hospital 52/ (24-82) 48.70 17.08 Israel 24,067 Ard Hospital 62/ (45-59) 18.18 - Zuo, Zuo 2020-05-29 USA 44 Hospital 57/ (45-59) 18.18 - Chaudhry 2020-05-29 USA 22 Hospital 65/ (55-77)	Assnami 2020-05-19 Arabia 128 Centre (24-55) 53.90 15.22 - Russell 2020-05-19 UK 106 Hospital 67 (52-81) 45.30 6.60 - Berumen 2020-05-26 Mexico 102,875 Hospital - 49.08 - 9.64 Gianfrances co 2020-05-28 Multiple 600 Community and Hospital 56 (46-67) 71.00 - 21.50 Li, Long 2020-05-28 China 145 Not Stated 490/6 61.00 - 55.21 Batty 2020-06-01 UK 908 Hospital 72.77 (46-66) 44.27 11.23 - Israel 2020-05-29 USA 1,484 Hospital 62 (52.72) 40.60 5.53 - Zuo, Zuo 2020-05-29 USA 44 Hospital 65 (55.77) 18.18 - 27.27 Chaudhry 2020-05-29 USA 40 Hospital end 615	Astramin 2020-05-19 Arabia 128 Centre (24,55) 53.90 15.62 - - Russell 2020-05-19 UK 106 Hospital 67 (52.81) 45.30 6.60 - 39.62 Berumen 2020-05-26 Mexico 102,875 Hospital 49.08 - 9.64 - Gianfrances co 2020-05-28 Multiple 600 Community Hospital 56 (45-67) 71.00 - 21.50 64.83 Li, Long 2020-05-28 China 145 Not Stated 49.04 (45-67) 44.27 11.23 - - Batty 2020-06-01 UK 908 Hospital 62 (25-72) 40.60 5.53 - - Israel 2020-05-29 USA 1,484 Hospital 62 (52-72) 40.60 5.53 - - Zuo, Zuo 2020-05-29 USA 44 Hospital 61 - 15.00 - Louis 2020-0	Astramin 2000-05-18 Arabia 1.26 Centre (24,55) 53.90 15.02 - </td <td>Ashami 2000-05-19 A_{rabia} 1.26 Centre (24,55) 53.90 15.82 - - - 62.03 Russell 2020-05-19 UK 106 Hospital $\frac{67}{(52-81)}$ 45.30 6.60 - 39.62 - 22.25 Berumen 2020-05-26 Mexico 102,875 Hospital - 49.08 - 9.64 - 90.36 0.00 Gianfrances 2020-05-28 Multiple 600 $\frac{66}{(45-67)}$ 71.00 - 21.50 64.83 - 94.48 Batty 2020-05-28 China 145 Not Stated $\frac{49}{(43-66)}$ 44.27 11.23 - - 94.48 Batty 2020-06-01 UK 908 Hospital $\frac{57}{(44-56)}$ 44.27 11.23 - - 90.36 0.00 Israel 2020-05-10 USA 1.48 Hospital $\frac{57}{(45-59)}$ 10.61 5.53 - - 77.16</td>	Ashami 2000-05-19 A_{rabia} 1.26 Centre (24,55) 53.90 15.82 - - - 62.03 Russell 2020-05-19 UK 106 Hospital $\frac{67}{(52-81)}$ 45.30 6.60 - 39.62 - 22.25 Berumen 2020-05-26 Mexico 102,875 Hospital - 49.08 - 9.64 - 90.36 0.00 Gianfrances 2020-05-28 Multiple 600 $\frac{66}{(45-67)}$ 71.00 - 21.50 64.83 - 94.48 Batty 2020-05-28 China 145 Not Stated $\frac{49}{(43-66)}$ 44.27 11.23 - - 94.48 Batty 2020-06-01 UK 908 Hospital $\frac{57}{(44-56)}$ 44.27 11.23 - - 90.36 0.00 Israel 2020-05-10 USA 1.48 Hospital $\frac{57}{(45-59)}$ 10.61 5.53 - - 77.16

Note. - Age not provided for total sample; ^ Denotes mean (SD).

Smoking prevalence by country

Unadjusted smoking prevalence in community and hospital studies compared with overall estimates for national adult smoking prevalence split by country is presented in Figure 2a and 2b. Lower than expected current and former smoking prevalence was generally observed, with similar to expected prevalence reported in studies conducted in the UK. Variability in prevalence estimates was observed across studies conducted in the US.




Figure 2a. Weighted average of current smoking prevalence in included studies (dashed lines) with 95% bootstrap confidence intervals compared with national current smoking prevalence (solid lines), split by country. Dot size corresponds to study sample size.




Figure 2b. Weighted average of former smoking prevalence in included studies (dashed lines) with 95% bootstrap confidence intervals compared with national former smoking prevalence (solid lines), split by country. Studies conducted in Mexico, Iran, Korea, Kuwait and Switzerland did not report former smoking prevalence. Dot size corresponds to study sample size.

SARS-CoV-2 infection by smoking status

Thirteen studies provided data on SARS-CoV-2 test results for people meeting local testing criteria by smoking status (see Table 2). Meta-analyses were performed for seven 'fair' quality studies (see Figure 3 and 4). Current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.73, 95% CI = 0.54-0.99, p = .046, I^2 = 93%). No significant difference was observed between former and never smokers (RR = 1.02, 95% CI = 0.88-1.18, p = .80, I^2 = 84%).




Figure 3. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers.




Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers.

Hospitalisation for COVID-19 by smoking status

Fourteen studies examined hospitalisation for COVID-19 disease stratified by smoking status (see Table 3). Meta-analyses were performed for five 'fair' quality studies (see Figure 5 and 6). There was no significant difference between current and never (RR = 1.12, 95% CI = $0.74-1.69, p = .48, I^2 = 84\%$) or former and never smokers (RR = 1.21, 95% CI = $0.82-1.79, p = .24, I^2 = 81\%$) in the risk of requiring admission to hospital with COVID-19.

	Current s	moker	Never	smoker				
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI	Weight
Argenziano	35	49	653	772		0.84	[0.71; 1.01]	21.9%
Hamer	93	37426	354	214828		1.51	[1.20; 1.89]	20.9%
Miyara	18	32	209	286	_	0.77	[0.56; 1.05]	18.7%
Rentsch	90	159	106	216	+	1.15	[0.95; 1.40]	21.7%
Yanover	30	514	132	3710		1.64	[1.12; 2.41]	16.8%
Random effects mode Heterogeneity: $l^2 = 84\%$, l		38180		219812		1.12	[0.74; 1.69]	100.0%
recordeneity. 7 = 0470, j				0.	5 1 2	3		

Figure 5. Forest plot for risk of hospitalisation in current vs. never smokers.




Figure 6. Forest plot for risk of hospitalisation in former vs. never smokers.

Disease severity by smoking status

T hirty-three studies reported disease severity in hospitalised patients stratified by smoking status (see T able 4). Severe (as opposed to non-severe) disease was broadly defined as requiring IT U admission, requiring oxygen as a hospital inpatient or in-hospital death (where this had not already been disaggregated into disease severity vs. mortality). Meta-analyses were performed for four 'fair' quality studies (see Figure 7 and 8). Current smokers were at increased risk of greater disease severity compared with never smokers (RR = 1.39, 95% CI = 1.09-1.77, p < .01, I² = 0%). No significant difference was observed between former and never smokers (RR = 1.40, 95% CI = 0.76-2.59, p = .28, I² = 74%).




Figure 7. Forest plot for the risk of severe disease in current vs. never smokers.




Figure 8. Forest plot for the risk of severe disease in former vs. never smokers.

Mortality by smoking status

Seventeen studies reported mortality from COVID-19 by smoking status (see Table 6), with three 'fair' quality studies. Meta-analyses were performed for two 'fair' quality studies with event data (see Figure 9 and 10). There was no significant difference between current and never (RR = 1.41, 95% CI = 0.91-2.20, p = .12, I² = 40%) or former and never smokers (RR = 0.98, 95% CI = 0.65-1.48, p = .93, I² = 0%) in the risk of mortality from COVID-19. The third 'fair' quality study reported hazard ratios adjusted for age and sex, suggesting an increased hazard of death in current (HR = 1.25, 95% CI = 1.12-1.40) and former (HR = 1.80, 95% CI = 1.70-1.90) compared with never smokers. In the adjusted primary analysis, the hazard in former smokers remained heightened (HR = 1.25, 95% CI = 1.18-1.33) but reversed in current smokers (HR = 0.88, 95% CI = 0.79-0.99). The result was not robust in unplanned sensitivity analyses including further adjustment for ethnicity, early censoring and complete data for smoking and BMI.

Study	Events				Risk Ratio	RR	95% CI	Weight
Al-Hindawi	1	1	3	8			[1.09; 6.27]	
Gaibazzi	10	21	132	376	+	1.36	[0.85; 2.17]	94.6%
Fixed effect model Heterogeneity: $I^2 = 40$		22		384 0.1	0.5 1 2	1.41 5	[0.91; 2.20]	100.0%

Figure 9. Forest plot for the risk of mortality in current vs. never smokers.

F	ormer sr	noker	Never sr	noker				
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI	Weight
Al-Hindawi	12	22	3	8	! •	1.45	[0.55; 3.85]	13.7%
Gaibazzi	14	44	132	376		0.91	[0.58; 1.43]	86.3%
Fixed effect model Heterogeneity: $I^2 = 0$ %	6. p = 0.3	66		384		0.98	[0.65; 1.48]	100.0%
				0.1	0.5 1 2	5		

Figure 10. Forest plot for the risk of mortality in former vs. never smokers.

		SARS-CoV	-2 negative					SARS-CoV	-2 positive				
Author	Total population tested	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Not stated (%)	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Not state (%)
Rentsch	3528*	2974* (84.30%)	1444 (48.55%)	704 (23.67%)	-	826 (27.77%)	-	554* (15.70%)	159 (28.70%)	179 (32.31%)	-	216 (38.99%)	-
Fontanet	661	490 (74.13%)	64 (13.06%)	-	-	426 (86.94%)	-	171 (25.87%)	5 (2.92%)	-		166 (97.08%)	-
Cho	1331	793 (59.58%)	142 (17.91%)	214 (26.99%)	-	437 (55.11%)		538 (40.42%)	111 (20.63%)	145 (26.95%)		282 (52.42%)	-
Shah	243**	212 (87.24%)	52 (24.53%)	47 (22.17%)	-	113 (53.30%)	-	29 (11.93%)	0 (0.00%)	9 (31.03%)	-	20 (68.97%)	-
Bello- Chavolla	62489	46960 (75.15%)	-	-	4835 (10.30%)		42125 (89.70%)	15529 (24.85%)	-	-	1374 (8.85%)		14155 (91.15%)
Kolin	1474***	805 (54.61%)	141 (17.52%)	307 (38.14%)	-	354 (43.98%)	3 (0.37%)	669 (45.39%)	72 (10.76%)	285 (42.60%)	-	303 (45.29%)	9 (1.35%)
de Lusignan	3291^	2740 (83.26%)	366 (13.36%)	1450 (52.92%)		924 (33.72%)		551 (16.74%)	47 (8.53%)	303 (54.99%)		201 (36.48%)	-
Valenti	789	689 (87.33%)	197 (28.59%)	-	-	-	492 (71.41%)	40 (5.07%)	7 (17.50%)	-	-	-	33 (82.50%)
Parrotta	76	39 (51.32%)	1 (2.56%)	10 (25.64%)	-	27 (69.23%)	1 (2.56%)	37 (48.68%)	1 (2.70%)	10 (27.03%)		25 (67.57%)	1 (2.70%)
Berumen	102875	71353 (69.36%)	-	-	7173 (10.05%)	64180 (89.95%)		31522 (30.64%)	-	-	2748 (8.72%)	28774 (91.28%)	-
Israel	24087	20076 (83.35%)	3711 (18.48%)	2670 (13.30%)	-	13695 (68.22%)		4011 (16.65%)	403 (10.05%)	471 (11.74%)		3137 (78.21%)	
del Valle	1108`	143 (12.91%)	27 (18.88%)	53 (37.06%)	-	-	63 (44.06%)	965 (87.09%)	55 (5.70%)	293 (30.36%)	-	-	617 (63.94%)

Table 2. SARS-CoV-2 infection by smoking status.

Note. Niedzwiedz et al. reported on SARS-CoV-2 infection by smoking status in multivariable analyses but did not present raw data; * Data on smoking status were missing for 261 participants; ** Data on smoking status were missing for 75 participants; *** Data on smoking status were missing for 12 participants; ^ Data on smoking status were missing for 511 participants; ` Data on smoking status were missing on 376 participants.

Table 3. Hospitalisation for COVID-19 by smoking status.

		Commun	ity						Hospita	lised					
Author	Population with outcome	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)
Rentsch	554	269 (48%)	69 (25.65%)	90 (33.46%)	-	110 (40.89%)	-	-	285 (51%)	90 (31.58%)	89 (31.23%)		106 (37.19%)	-	-
Petrilli	4103	2104 (51%)	108 (5.13%)	250 (11.88%)	-	-	1746 (82.98%)	-	1999 (48%)	104 (5.20%)	416 (20.81%)	-	-	1479 (73.99%)	-
Chow (US CDC)	6637	5143 (77%)	61 (1.19%)	80 (1.56%)		-	-	5002 (97.26%)	1494 (22%)	27 (1.81%)	78 (5.22%)	-	-	-	1389 (92.97%)
Argenziano	1000	151 (15%)	14 (9.27%)	18 (11.92%)	-	119 (78.81%)			849 (84%)	35 (4.12%)	161 (18.96%)		653 (76.91%)	-	
Miyara	470	139 (29%)	14 (10.07%)	41 (29.50%)		77 (55.40%)		7 (5.04%)	340 (72%)	18 (5.29%)	111 (32.65%)		209 (61.47%)		2 (0.59%)
Lubetzky	54	15 (27%)	-	-	4 (26.67%)	-	-	11 (73.33%)	39 (72%)	-	-	8 (20.51%)	-	-	31 (79.49%)
Carrillo-Vega	9946	3922 (39%)	408 (10.40%)	-	-	-	-	3514 (89.60%)	6024 (60%)	486 (8.07%)	-	-	-	-	5538 (91.93%)
Yanover	4353	4180 (96%)	484 (11.58%)	118 (2.82%)	-	3578 (85.60%)			173 (3%)	30 (17.34%)	11 (6.36%)	-	132 (76.30%)		
Hamer	387109	386349 (99%)	37333 (9.66%)	134542 (34.82%)	-	214474 (55.51%)			760 (0%)	93 (12.24%)	313 (41.18%)	-	354 (46.58%)		
Heili-Frades	4712	1973 (41%)	121 (6.13%)	222 (11.25%)	-	-	1630 (82.62%)	1630 (82.62%)	2739 (58%)	112 (4.09%)	598 (21.83%)	-	-	2029 (74.08%)	-
Freites	123	69 (56%)	1 (1.45%)	-	-	-	-	68 (98.55%)	54 (43%)	3 (5.56%)	-	-	-	-	51 (94.44%)
Berumen	102875	18832 (18%)	-	-	1546 (8.21%)	-	17286 (91.79%)	-	12690 (12%)	-	-	1202 (9.47%)	-	11488 (90.53%)	-
Gianfrancesco	600	323 (53%)	-	-	61 (18.89%)	-	-	262 (81.11%)	277 (46%)	-	-	68 (24.55%)	-	-	209 (75.45%)
Chaudhry	40	19 (47%)		-	0 (0.00%)	-		19 (100.00%)	21 (52%)	-		6 (28.57%)		-	15 (71.43%)

Note. * Data on smoking status were missing for 31 participants; ** Data on smoking status were missing for 9 participants; ^ 22 individuals died in the emergency department and were thus not hospitalised but are included in the community sample; 'Data on outcomes were missing for 525 participants.

		Non sev	ere disease						Severe	disease					
Author	Population with severity	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)
Guan, Ni	1085°	913 (84%)	108 (11.83%)	12 (1.31%)	-	793 (86.86%)		-	172 (15%)	29 (16.86%)	9 (5.23%)		134 (77.91%)	-	-
Zhang, Dong	9 ^b	3 (33%)	0 (0.00%)	3 (100.00%)	-	0 (0.00%)	-	-	6 (66%)	2 (33.33%)	4 (66.67%)	-	0 (0.00%)	-	-
Wan	9°	8 (88%)	8 (100.00%)	0 (0.00%)	-	0 (0.00%)	-	-	1 (11%)	1 (100.00%)	0 (0.00%)	-	0 (0.00%)	-	-
Huang, Wang	3 ^d	3 (100%)	3 (100.00%)	0 (0.00%)	-	0 (0.00%)			0 (0%)	0 (-)	0 (-)	-	0 (-)	-	-
Rentsch	285	168 (58%)	47 (27.98%)	53 (31.55%)	-	68 (40.48%)	-	-	117 (41%)	43 (36.75%)	36 (30.77%)	-	38 (32.48%)	-	-
Hu	323	151 (46%)	-	-	12 (7.95%)	-	139 (92.05%)	-	172 (53%)	-	-	26 (15.12%)	-	146 (84.88%)	-
Wang, Pan	125	100 (80%)	-	-	9 (9.00%)	-	91 (91.00%)	-	25 (20%)	-	-	7 (28.00%)	-	18 (72.00%)	-
Petrilli	1278	932 (72%)	62 (6.65%)	175 (18.78%)	-	-	391 (41.95%)	-	650 (50%)	28 (4.31%)	145 (22.31%)	-	-	477 (73.38%)	-
Kim	27°	21 (77%)	3 (14.29%)		-	-	18 (85.71%)	-	6 (22%)	2 (33.33%)	0 (0.00%)	-	-	4 (66.67%)	-
Shi, Yu	474 ^t	425 (89%)	-		34 (8.00%)	-	391 (92.00%)	-	49 (10%)	-	-	6 (12.24%)	-	43 (87.76%)	-
Liao, Feng	148 ⁹	92 (62%)			5 (5.43%)	-		87 (94.57%)	56 (37%)	3 (5.36%)	-	-	-	-	53 (94.64%)
Shi, Ren	134	88 (65%)			8 (9.09%)	-	-	80 (90.91%)	46 (34%)		-	6 (13.04%)	-	-	40 (86.96%)
Hadjadj	50	15 (30%)	1 (6.67%)	2 (13.33%)	-	12 (80.00%)	-	-	35 (70%)	0 (0.00%)	7 (20.00%)	-	28 (80.00%)	-	-
Zheng, Xiong	73	43 (58%)	-	-	6 (13.95%)	37 (86.05%)	-	-	30 (41%)	-	-	2 (6.67%)	28 (93.33%)	-	-
de la Rica	48	26 (54%)	-	-	6 (23.08%)	-	-	20 (76.92%)	20 (41%)	-	-	4 (20.00%)	-	-	16 (80.00%)
Yin, Yang	106	47 (44%)	-	-	6 (12.77%)	-	-	41 (87.23%)	59 (55%)	-	-	12 (20.34%)	-	-	47 (79.66%)

Table 4. Disease severity by smoking status.

Aller	nbach	147 ^h	100 (68%)		-	9 (9.00%)		-	91 (91.00%)	47 (31%)	-	-	0 (0.00%)	-	-	47 (100.00%)
Goy	ral	393	263 (66%)	14 (5.32%)		-	-	-	249 (94.68%)	130 (33%)	6 (4.62%)	-	-	-	-	124 (95.38%)
Fen	g	454 ⁱ	333 (73%)	27 (8.11%)	-	-	-	-	306 (91.89%)	121 (26%)	17 (14.05%)	-	-	-	-	104 (85.95%)
Yao		108	83 (76%)	1 (1.20%)	-	-		-	82 (98.80%)	25 (23%)	3 (12.00%)	-	-	-	-	22 (88.00%)
San	ni	490	400 (81%)	53 (13.25%)	-	-	-	-	347 (86.75%)	90 (18%)	16 (17.78%)	-	-	-	-	74 (82.22%)
Reg	jina	200	163 (81%)	9 (5.52%)	-	-	-	-	154 (94.48%)	37 (18%)	0 (0.00%)	-	-	-	-	37 (100.00%)
Feu	th	28	21 (75%)	1 (4.76%)	7 (33.33%)	-	13 (61.90%)	-		7 (25%)	2 (28.57%)	1 (14.29%)	-	4 (57.14%)	-	-
Meji Vilet	ia- t	329	214 (65%)		-	13 (6.07%)	-	-	201 (93.93%)	115 (34%)		-	10 (8.70%)	-	-	105 (91.30%)
Che Jian		135	54 (40%)	-	-	4 (7.41%)	-	-	50 (92.59%)	81 (60%)	-	-	9 (11.11%)	-	-	72 (88.89%)
Vaq Ron	uero- icero	146	75 (51%)	-	-	4 (5.33%)	-	-	71 (94.67%)	71 (48%)	-	-	6 (8.45%)	-	-	65 (91.55%)
Kim Gar	, g	2490	1692 (67%)	112 (6.62%)	395 (23.35%)	-	-	1185 (70.04%)		798 (32%)	38 (4.76%)	247 (30.95%)		-	512 (64.16%)	-
Wu		174	92 (52%)	-	-	47 (51.09%)	-	45 (48.91%)	-	82 (47%)	11 (13.41%)	-	-	-	71 (86.59%)	-
Rus	sell	106	87 (82%)	6 (6.90%)	22 (25.29%)	-	35 (40.23%)	-	24 (27.59%)	19 (17%)	1 (5.26%)	4 (21.05%)	-	7 (36.84%)	-	7 (36.84%)
Cha	udhry	40	34 (85%)	-	-	5 (14.71%)	-	-	29 (85.29%)	6 (15%)	-	-	1 (16.67%)	-	-	5 (83.33%)
Pate	el	104	67 (64%)	25 (37.31%)	-		-	36 (53.73%)	6 (8.96%)	37 (35%)	18 (48.65%)	-	-	-	15 (40.54%)	4 (10.81%)
Gari	ibaldi	832	532 (63%)	25 (4.70%)	107 (20.11%)	-	-	-	400 (75.19%)	300 (36%)	21 (7.00%)	81 (27.00%)	-	-	-	198 (66.00%)

Note. a Data on smoking status were missing for 14 participants; b Data on smoking status were missing for 131 participants; c Data on smoking status were missing for 126 participants; d Data on smoking status were missing for 38 participants; e Data on smoking status were missing for 1 participant; f Data on smoking status were missing for 13 participants; g Data on smoking status were missing for 1700 participants; h Data on smoking status were missing for 5 participants; i Data on smoking status were missing for 21 participants; j Data on smoking status were missing for 1 participant; * Patients with disease requiring hospital (but not ITU) admission.

		Recove	red						Died						
Author	Population with mortality	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)	N (%)	Current smoker (%)	Former smoker (%)	Current/former smoker (%)	Never smoker (%)	Never/unknown smoker (%)	Not stated (%)
Chen	274*	161 (58%)	5 (3.11%)	5 (3.11%)	-	-	-	151 (93.79%)^	113 (41%)	7 (6.19%)	2 (1.77%)	-	-	-	104 (92.04%)
Zhou, Yu	191	137 (71%)	6 (4.38%)	-	-	-	-	131 (95.62%)	54 (28%)	5 (9.26%)	-	-	-	-	49 (90.74%)
Yang, Yu	52	20 (38%)	2 (10.00%)	-	-	-	18 (90.00%)	-	32 (61%)	-	-	-	-	32 (100.00%)	-
Gaibazzi	441	285 (64%)	11 (3.86%)	30 (10.53%)	-	244 (85.61%)	-		156 (35%)	10 (6.41%)	14 (8.97%)	-	132 (84.62%)	-	-
Borobia	2226	1766 (79%)	113 (6.40%)	-	-	-	-	1653 (93.60%)	460 (20%)	44 (9.57%)	-	-	-	-	416 (90.43%)
Giacomelli	233	185 (79%)	-		53 (28.65%)	132 (71.35%)	-		48 (20%)	-	-	17 (35.42%)	31 (64.58%)	-	0 (0.00%)
Yao	108	96 (88%)	1 (1.04%)	-	-	-	-	95 (98.96%)	12 (11%)	3 (25.00%)	-	-	-	-	9 (75.00%)
Carillo- Vega	9946**	8983 (90%)	795 (8.85%)		-		-	8188 (91.15%)	963 (9%)	99 (10.28%)	-	-	-	-	864 (89.72%)
Heng	51	39 (76%)	6 (15.38%)		-	-	-	33 (84.62%)	12 (23%)	1 (8.33%)	-	-	-	-	11 (91.67%)
Heili- Frades	4712	4086 (86%)	210 (5.14%)	659 (16.13%)	-	-	3217 (78.73%)	-	626 (13%)	23 (3.67%)	161 (25.72%)		-	442 (70.61%)	
Kim, Garg	2490	2070 (83%)	128 (6.18%)	481 (23.24%)	-	-	1461 (70.58%)		420 (16%)	22 (5.24%)	161 (38.33%)	-	-	236 (56.19%)	-
Al- Hindawi	31	15 (48%)	0 (0.00%)	10 (66.67%)	-	5 (33.33%)			16 (51%)	1 (6.25%)	12 (75.00%)		3 (18.75%)		
Louis	22	16 (72%)	-	-	7 (43.75%)	-	-	9 (56.25%)	6 (27%)	-	-	3 (50.00%)	-	-	3 (50.00%)
Soto-Mota	400	200 (50%)	-	-	23 (11.50%)	-		177 (88.50%)	200 (50%)	-	-	25 (12.50%)	-		175 (87.50%)
Garibaldi	747***	634 (84%)	36 (5.68%)	129 (20.35%)	-	-	-	469 (73.97%)	113 (15%)	6 (5.31%)	36 (31.86%)	-	-	-	71 (62.83%)
Docherty	13364`	8199 (61%)	370 (4.51%)	1832 (22.34%)		4179 (50.97%)		1818 (22.17%)	5165 (38%)	214 (4.14%)	1350 (26.14%)		2105 (40.76%)		1496 (28.96%)

Note. Solis et al. and the OpenSAFELY Collaborative reported on mortality by smoking status in a multivariable analysis but did not present raw data on both exposure and outcome; * Data on smoking status were missing for 274 participants; ** Data on smoking status were missing for 598 participants; *** Data on smoking status were missing for 85 participants; ` Data on smoking status were missing for 6769 participants; ^ No smoking history defined as <30 pack-years of smoking.

Discussion

This rapid review of 102 studies found substantial uncertainty arising from the recording of smoking status. Notwithstanding these uncertainties, compared with overall adult national prevalence estimates, recorded current and former smoking rates in most countries were lower than expected. From available data, there was insufficient evidence to conclude that current and/or former smoking status is associated with hospitalisation or mortality. There was some evidence from 'fair' quality studies that the risk of SARS-CoV-2 infection is reduced, and disease severity in those hospitalised for COVID-19 is greater, in current but not former smokers compared with never smokers.

Infection by smoking status

In seven 'fair' quality studies, evidence suggest that current (but not former) smokers in the community are less likely to test positive for SARS-CoV-2 compared with never smokers. It should be noted that criteria for accessing testing will vary during the course of the epidemic. It is possible that current and former smokers are more likely to receive a test due to increased prevalence of cough or altered sense of smell or taste¹²⁵, which are used as screening criteria. Infection positivity rates estimated among random

samples will be more informative than currently available data. Smoking status is being collected in at least one large representative infection and antibody survey in the UK¹²⁶.

Hospitalisation and disease severity by smoking status

As reported elsewhere16, smoking prevalence among multiple hospital and community cohorts was consistently lower than national estimates from China, USA, France, Spain, Israel, Italy, Mexico, Finland, Iran, Kuwait and Switzerland. In a single study conducted in Korea and nine studies of varying quality conducted in the UK, however, current and former smoking rates were similar to those expected.

In five 'fair' quality studies across four countries, there was no evidence that current or former smokers are at lower risk of hospitalisation for COVID-19 compared with never smokers among those identified as testing positive. There was some evidence from four 'fair' quality studies that current smokers are at increased risk of greater disease severity compared with never smokers.

Mortality by smoking status

In three 'fair' quality studies, there was inconsistent evidence on the association of smoking status and the risk of death from COVID-19. Given lack of knowledge of the disease progression and long-term outcomes of COVID-19 disease, it is unclear whether studies conducted thus far in the pandemic have monitored patients for a sufficient time period to report complete survival outcomes or whether this reflects early censoring.

Issues complicating interpretation

Interpretation of these early studies is complicated by several factors (see Figure 11). First, exposure to SARS-CoV-2 is heterogeneous with different subgroups being at heightened risk of infection at different stages of the pandemic. This will likely introduce bias in studies assessing the rate of infection by smoking status conducted early on. Second, as mentioned above, current and former smokers may be more likely to meet local criteria for community testing due to increased prevalence of symptoms consistent with SARS-CoV-2 infection, such as cough, increased sputum production or altered sense of smell or taste125. Third, testing for acute infection requires swabbing of the mucosal epithelium, which may be disrupted in current smokers, potentially altering the sensitivity of assays⁸⁷. Fourth, most included studies relied on electronic health records (EHRs) as the source of information on smoking status. Research shows large discrepancies between EHRs and actual behaviour¹²⁷. Known failings of EHRs include implausible longitudinal changes, such as former smokers being recorded as never smokers at subsequent hospital visits¹²⁷. Misreporting on the part of the patient (perhaps due to perceived stigmatisation) has also been observed, with biochemical measures showing higher rates of smoking compared with self-report in hospitalised patients in the US128. It is hence possible that under-reporting of current and former smoking status occurred across the included studies. Fifth, individuals with severe COVID-19 symptoms may have stopped smoking prior to admission to a care facility and may therefore not have been recorded as current smokers (i.e. reverse causality).

Sixth, smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present to hospital due to lack of access to healthcare and may be more likely to die in the community from sudden complications (i.e. self-selection bias) and thus not be recorded. Seventh, if there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt nicotine withdrawal upon hospitalisation may lead to worse outcomes¹². Eight, during periods of heightened demand of limited healthcare resources, current smokers with extensive comorbidities may have reduced priority for intensive care admission, thus leading to higher in-hospital mortality.

Another important issue is that the reason for hospitalisation varies by country and time in the pandemic. For example, early cases may have been hospitalised for isolation and quarantine reasons and not due to medical necessity. It is plausible that this may have skewed early data towards less severe cases. In addition, the observed association between current smoking and disease severity may be explained by collider bias129, where conditioning on a collider (e.g. testing or hospitalisation) by design or analysis may introduce a spurious association between smoking (a potential cause of testing or hospitalisation) and SARS-CoV-2 infection/adverse outcomes from COVID-19 (potentially exacerbated by smoking)¹³⁰.




Figure 11. A schematic of some of the interpretation issues for the association of smoking and SARS-CoV-2/COVID-19. * Indicates potential confounding with smoking status.

Limitations

This rapid review was limited by not having two independent reviewers extracting data, limiting the search to one electronic database and one pre-print server and by not including at least three large population surveys due to their reliance on self-reported SARS-CoV-2 infection (which means they are not meeting our eligibility criteria)^{125,131,132}. Population surveys – particularly with linked health data – will be included in future review versions to help mitigate some of the limitations of healthcare based observational studies. The comparisons with national estimates of smoking prevalence did not adjust observed prevalence for the demographic profile of those admitted/tested. Other reviews focused on this comparison have applied adjustment for sex, and continue to find lower than expected prevalence – notwithstanding the issues complicating interpretation described above¹⁶.

Implications for research, policy and practice

Further scientific research is needed to resolve the mixed findings summarised in our review. First, clinical trials of the posited therapeutic effect of nicotine could have important implications both for smokers and for improved understanding of the SARS-CoV-2 virus. Such trials should focus on medicinal nicotine (as smoked tobacco is a dirty delivery mechanism that could mask beneficial effects) and potentially differentiate between different modes of delivery (i.e. inhaled vs. not) since this can affect pharmacokinetics¹³³ and potential therapeutic effects. A second research priority would be a large, representative (randomly sampled) population survey with a validated assessment of smoking status which distinguishes between recent and long-term exsmokers – ideally biochemically verified – and assesses seroprevalence and links to health records.

In the meantime, public-facing messages about the possible protective effect of smoking or nicotine are premature. In our view, until there is further research, the quality of the evidence does not justify the huge risk associated with a message likely to reach millions of people that a lethal activity, such as smoking, may protect against COVID-19. It continues to be appropriate to recommend smoking cessation and emphasise the role

of alternative nicotine products to support smokers to stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces acute risks from cardiovascular disease and could reduce demands on the healthcare system¹³⁴. GPs and other healthcare providers can play a crucial role – brief, high-quality and free online training is available at National Centre for Smoking Cessation and Training.

Conclusion

Across 102 studies, there is substantial uncertainty arising from the recording of smoking status on whether current and/or former smoking status is associated with SARS-CoV-2 infection, hospitalisation or mortality. There is some evidence that current smoking compared with never is associated with reduced risk of testing positive in the community but greater disease severity in those hospitalised for COVID-19.

Acknowledgements

An original short review for the Royal College of Physicians was converted to an extended living review after a request by Martin Dockrell, Tobacco Control Lead, Public Health England. All scientific decisions were made by the authors independently of funders and external organisations. The authors would like to thank Rosemary Koper for her assistance in running the electronic searches and data extraction.

Declaration of conflicts of interest

DS and OP have no conflicts of interest to declare. LS has received a research grant and honoraria for a talk and travel expenses from manufacturers of smoking cessation medications (Pfizer and Johnson & Johnson). JB has received unrestricted research funding from Pfizer to study smoking cessation.

Funding statement

DS is supported by a PhD studentship from the UK Biotechnology and Biological Sciences Research Council (BB/M009513/1). OP receives salary support from Cancer Research UK (C1417/A22962). JB, LS, & OP are members of SPECT RUM, a UK Prevention Research Partnership Consortium (MR/S037519/1). UKPRP is an initiative funded by the UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities.

References

1 Guan W, Ni Z, Hu YY, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; : NEJMoa2002032.

2 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; published online March 5. DOI:10.1016/j.cell.2020.02.052.

3 Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med 2020, Vol 9, Page 841 2020; 9: 841.

4 Cai G. Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov. 2020; published online March 2. DOI:10.20944/PREPRINT S202002.0051.V3.

5 Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the reninangiotensin system. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 2018; 315: R895–906.

6 Denholm JT, Gordon CL, Johnson PD, et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 2010; 192: 84–6.

7 Abadom T R, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study. Vaccine 2016; 34: 5649–55.

8 Almirall J, González CA, Balanzó X, Bolíbar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375–9.

9 Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J. Infect. 2013; 67: 169–84.

10 Dye JA, Adler KB. Occasional review Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994; 49: 825–34.

11 Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020; 18: 20.

12 Farsalinos K, Niaura R, Le Houezec J, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Reports 2020; published online April. DOI:10.1016/j.toxrep.2020.04.012.

13 Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020; 8: e35.

14 Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. medRxiv 2020; : 2020.03.25.20043745. 15 Patanavanich R, Glantz SA. Smoking is Associated with COVID-19 Progression: A Meta-Analysis. medRxiv 2020. DOI:10.14171/j.2095-5944.sg.2014.02.004.

16 Farsalinos K, Barbouni A, Niaura R. Smoking, vaping and hospitalization for COVID-19. Qeios 2020; published online March 25. DOI:10.32388/Z6908A.8.

17 Berlin I, Thomas D, Le Faou A-L, Cornuz J. COVID-19 and Smoking. Nicotine Tob Res DOI:10.1093/NTR/NTAA059.

Elliott JH, Turner T, Clavisi O, et al. Living Systematic Reviews: An Emerging
 Opportunity to Narrow the Evidence-Practice Gap. PLoS Med 2014; 11.
 DOI:10.1371/journal.pmed.1001603.

19 Tricco AC, Antony J, Zarin W, et al. A scoping review of rapid review methods. BMC Med 2015; 13: 224.

20 National Heart Lung and Blood Institute. Study Quality Assessment Tools. Natonal Institutes Heal. 2018; : 1–35.

21 R Core Team. The R Project for Statistical Computing. 2013; : 1–12.

22 Higgins JPT, Wells GA. Cochrane handbook for systematic reviews of interventions. 2011.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br. Med. J. 2003; 327: 557–60.

Efron B. Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: 171–85.

25 Miyara M, Tubach F, Pourcher V, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios 2020; published online April 21. DOI:10.32388/WPP19W.3.

Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020; : 2000547.

Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older
 Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. Clin Infect Dis 2020;
 2019: 1–8.

Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; published online March 24. DOI:10.1136/gutjnl-2020-320926.

29 Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 2020; 368: m1295.

30 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 0. DOI:10.1016/s0140-6736(20)30566-3.

31 Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19

pneumonia in Wuhan, China. Clin Infect Dis 2020; published online March 16. DOI:10.1093/cid/ciaa270.

32 Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; : all.14238.

33 Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; : 1–10.

Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; 133: 1.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.

³⁶ Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020; 94: 81–7.

Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of
 Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 2019.
 DOI:10.1001/jamacardio.2020.1017.

Liu R, Ming X, Zhu H, et al. Association of Cardiovascular Manifestations with Inhospital Outcomes in Patients with COVID-19: A Hospital Staff Data. medRxiv 2020; : 2020.02.29.20029348.

39 Xu HH, Hou K, Xu HH, et al. Acute Myocardial Injury of Patients with Coronavirus Disease 2019. medRxiv 2020; : 2020.03.05.20031591.

Li J, Li S, Cai Y, et al. Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. medRxiv 2020; : 2020.02.11.20022053.

41 Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv 2020; : 2020.04.09.20059964.

42 Hu L, Chen S, Fu Y, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China. medRxiv 2020; : 2020.03.25.20037721.

43 Wang R, Pan M, Zhang X, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis 2020; : 127065.

Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv 2020; : 2020.04.08.20057794.

45 Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. Morb Mortal Wkly Rep 2020; 69: 382–6.

46 Dong X, Cao Y, Lu X, et al. Eleven Faces of Coronavirus Disease 2019. Allergy 2020; : 1–11.

47 Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci 2020; 35: e142.

48 Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. Crit Care 2020; 24: 2–5.

49 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 2600: 1–7.

Argenziano MG, Bruce SL, Slater CL, et al. Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. medRxiv 2020; : 2020.04.20.20072116.

51 Solis P, Carreno H. COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients in Mexico. 2020. DOI:10.1101/2020.04.21.20074591.

Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
 New York City Area. JAMA 2020; 10022: 1–8.

53 Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv 2020; : 2020.04.18.20071134.

54 Zheng KI, Gao F, Wang X-B, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 2020; : 154244.

Liao Y, Feng Y, Wang B, et al. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fang cang shelter Hospital : a retrospective , Summary : 2020; : 1–16.

56 Rodriguez-Cola M, Jimenez-Velasco I, Gutierrez-Henares F, et al. Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury. 2020. DOI:10.1101/2020.04.20.20072918.

57 Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020; : 2020.04.16.20065920.

58 Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and secondgeneration COVID-19 cases outside Wuhan, China: A multicenter retrospective study.

2020. DOI:10.1101/2020.04.19.20071472.

59 Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv 2020; : 2020.04.19.20068015.

Niedzweidz C, O'Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences
 in SARS-CoV-2 infection: prospective cohort study using UK Biobank. 2020.
 DOI:10.1101/2020.04.22.20075663.

Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, Silva J. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia , March 2020. 2020; 69. https://www.cdc.gov/mmwr/volumes/69/wr/mm6918e1. htm? s_cid=mm6918e1_w.

62 Yu T, Cai S, Zheng Z, et al. Association between clinical manifestations and prognosis in patients with COVID-19. Clin Ther 2020; xxx: 1–9.

63 Zheng Y, Xiong C, Liu Y, et al. Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020. Pharmacol Res 2020; 157: 104821.

64 Rica R de la, Borges M, Aranda M, et al. Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study. medRxiv 2020; : 1–35.

45 Yin R, Yang Z, Wei Y, et al. Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: a retrospective study. medRxiv 2020; : 2020.04.29.20085415.

66 Gaibazzi N, Tuttolomondo D, Guidorossi A, et al. Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19. medRxiv 2020; : 2020.05.05.20092015.

67 Shi H, Zuo Y, Yalavarthi S, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 Hui. medRxiv 2020; : 1–15.

68 Cho ER, Jha P. Smoking and the risk of COVID-19 infection in the UK Biobank Prospective Study. 2020; : 10–3.

69 Allenbach Y, Saadoun D, Maalouf G, et al. Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients. medRxiv 2020; : 2020.05.04.20090118.

70 Robilotti E V, Babady NE, Ph D, et al. Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv 2020; : 1–19.

71 Collaborative TO, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020; : 2020.05.06.20092999.

72 Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M. A

cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv 2020. DOI:10.1101/2020.04.29.20080853.

Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. medRxiv 2020; : 1–25.

74 Shah SJ, Barish PN, Prasad PA, et al. illness : a comparison of patients with and without COVID-19. 2020.

Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Predicting mortality
 attributable to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID 19 outcomes in Mexico. medRxiv 2020; 52: 2020.04.20.20072223.

Kolin DA, Kulm S, Elemento O. Clinical and Genetic Characteristics of Covid-19Patients from UK Biobank. medRxiv 2020; : 2020.05.05.20075507.

Lubetzky M, Aull M, Craig-Shapiro R, et al. Kidney Allograft Recipients Diagnosed
with Coronavirus Disease-2019 : A Single Center Report. medRxiv 2020; :
2020.04.30.20086462.

Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020; published online April 17. DOI:10.1056/nejmc2010419.

79 Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med 2020; : 1–53.

Yao Q, Wang P, Wang X, et al. Retrospective study of risk factors for severe
 SARS-Cov-2 infections in hospitalized adult patients. Polish Arch Intern Med 2020.
 DOI:10.20452/pamw.15312.

Sami R, Soltaninejad F, Amra B, et al. A one-year hospital-based prospective
 CVOID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort
 (KCC) study. medRxiv 2020; : 2020.05.11.20096727.

Almazeedi S, Youha S Al, Jamal MH, et al. Clinical Characteristics, Risk Factors and Outcomes Among the First Consecutive 1,096 Patients Diagnosed with COVID-19: The Kuwait Experience. medRxiv 2020; : 2020.05.09.20096495.

83 Carrillo-Vega MF, Salinas-Escudero G, Garcia-Peña C, Gutierrez-Robledo LM, Parra-Rodriguez L, Fernanda M. Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico. medRxiv 2020; : 2020.05.11.20098145.

84 Yanover AC, Mizrahi B, Kalkstein N, Marcus K, Akiva P, Barer Y. What factors increase the risk of complications in SARS-CoV-2 positive patients? A cohort study in a nationwide Israeli health organization. 2020.

Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle Risk Factors for
 Cardiovascular Disease in Relation to COVID-19 Hospitalization : A Community-Based
 Cohort Study of 387 , 109 Adults in UK Division of Surgery and Interventional Sciences ,

Faculty Medical Sciences , University College London , L. 2020; : 1–11.

86 Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. medRxiv 2020; : 2020.05.11.20097741.

de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis 2020; 0. DOI:10.1016/S1473-3099(20)30371-6.

88 Targher G, Mantovani A, Wang X-B, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020; published online May 13. DOI:10.1016/j.diabet.2020.05.001.

Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy
blood donors during the COVID-19 Milan outbreak. medRxiv 2020; :
2020.05.11.20098442.

Feuth T, Saaresranta T, Karlsson A, et al. Is sleep apnoea a risk factor for CovidFindings from a retrospective cohort study. medRxiv 2020; : 2020.05.14.20098319.

Ge H, Zhu M, Du J, et al. Cardiac Structural and Functional Characteristics in
 Patients with Coronavirus Disease 2019: A Serial Echocardiographic Study. medRxiv 2020;
 : 2020.05.12.20095885.

92 Parrotta E, Kister I, Charvet L, et al. COVID-19 OUT COMES IN MS EARLY EXPERIENCE FROM NYU MULT IPLE SCLEROSIS COMPREHENSIVE CARE CENTER. medrxiv 2020; : 1–9.

93 Shekhar R, Upadhyay S, Sheikh A, Atencio J, Kapuria D. Early experience with COVD-19 patients at tertiary care teaching hospital in southwestern United states. medrxiv 2020; : 1–15.

94 Mejia-Vilet JM, Cordova-Sanchez BM, Fernandez-Camargo D, Mendez-Perez RA, Morales-Buenrostro LE, Hernandez-Gilsoul T. DERIVATION OF A SCORE TO PREDICT ADMISSION TO INTENSIVE CARE UNIT IN PATIENTS WITH COVID-19: THE ABC-GOALS SCORE. medRxiv 2020; : 2020.05.12.20099416.

95 Chen C, Jiang J, Xu X, Hu Y, Hu Y, Zhao Y. Dynamic liver function indexes monitoring and clinical characteristics in three types of COVID-19 patients. medRxiv 2020; : 2020.05.13.20099614.

Li J, Chen Y, Chen S, et al. Derivation and validation of a prognostic model for predicting in-hospital mortality in patients admitted with COVID-19 in Wuhan China the PLANS (Platelet Lymphocyte Age Neutrophil Sex) model. medrxiv 2020; : 2020.05.13.20100370.

97 Rimland CA, Morgan CE, Bell GJ, et al. Clinical characteristics and early outcomes

in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv 2020; : 2020.05.13.20100404.

Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher
 in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York.
 Metabolism 2020; 108: 154262.

99Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and Tocilizumab Therapy inCOVID-19 Patients - An Observational Study. medRxiv 2020; : 2020.05.21.20109207.

Heili-Frades S, Minguez P, Mahillo-Fernandez I, et al. COVID-19 Outcomes in 4712
consecutively confirmed SARS-CoV2 cases in the city of Madrid. medRxiv 2020; :
2020.05.22.20109850.

101 Vaquero LM, Barrado MES, Escobar D, et al. C-Reactive protein and SOFA score as early predictors of critical care requirement in patients with COVID-19 pneumonia in Spain. medRxiv 2020; : 2020.05.22.20110429.

Kim L, Garg S, O'Halloran A, et al. Interim Analysis of Risk Factors for Severe
 Outcomes among a Cohort of Hospitalized Adults Identified through the U.S.
 Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network
 (COVID-NET). medRxiv 2020; : 2020.05.18.20103390.

103 Wu MA, Fossali T, Pandolfi L, et al. COVID-19 the key role of pulmonary capillary leakage. An observational cohort study. medrxiv 2020; : 2020.05.17.20104877.

104 Shi Q, Zhao K, Yu J, et al. Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study. medRxiv 2020; : 2020.03.04.20031039.

105 Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv 2020; : 2020.05.15.20103531.

106 Al-Hindawi A, Sokhi J, Cuddihy J, et al. COVID-19 in London a Case Series Demonstrating Late Improvement in Survivors. medrxiv 2020; : 2020.05.16.20103853.

107 Basse C, Diakite S, Servois V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. medRxiv 2020; : 2020.05.14.20101576.

108 Freites D, Leon L, Mucientes A, et al. Risk factors for hospital admission related to COVID-19 in inflammatory rheumatic diseases. medRxiv 2020; : 2020.05.14.20101584.

109 Alshami AA, Alattas RA, Anan HF, et al. Silent Disease and Loss of Taste and Smell are Common Manifestations of SARS-COV-2 Infection in a Quarantine Facility: First report from Saudi Arabia. medRxiv 2020; : 2020.05.13.20100222.

Russell B, Moss C, Papa S, et al. Factors affecting COVID-19 outcomes in cancer
patients – A first report from Guys Cancer Centre in London. medRxiv 2020; :
2020.05.12.20094219.

111 Berumen J, Schmulson M, Alegre J, et al. Risk of infection and hospitalization by Covid-19 in Mexico: a case-control study. medRxiv 2020; : 2020.05.24.20104414. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; published online May 29. DOI:10.1136/annrheumdis-2020-217871.

Li J, Long X, Zhu C, et al. Olfactory dysfunction in recovered COVID-19 patients.Mov Disord 2020; : mds.28172.

114 Batty GD, Deary I, Luciano M, Altschul D, Kivimaki M, Gale C. Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study of the general population. medRxiv 2020; : 2020.05.29.20100735.

Israel A, Feldhamer I, Lahad A, Levin-Zamir D, Lavie G. Smoking and the risk of
COVID-19 in a large observational population study. medRxiv 2020; :
2020.06.01.20118877.

116 Valle DM Del, Kim-schulze S, Hsin-hui H, et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. medRxiv 2020; : 2020.05.28.20115758.

117 Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv 2020; : 2020.04.30.20086736.

118 Chaudhry F, Bulka H, Rathnam AS, et al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. medRxiv 2020; : 2020.05.27.20114827.

Louis S, Dhawan A, Newey C, et al. Continuous Electroencephalography (cEEG)
 Characteristics and Acute Symptomatic Seizures in COVID-19 Patients. medRxiv 2020; :
 2020.05.26.20114033.

120 Soto-Mota A, Garza BAM, Rodriguez EM, et al. THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY. medRxiv 2020; : 2020.05.26.20111120.

Patel M, Gangemi A, Marron R, et al. Use of High Flow Nasal Therapy to Treat
Moderate to Severe Hypoxemic Respiratory Failure in COVID-19. medRxiv 2020; :
2020.05.22.20109355.

Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region. medRxiv 2020; : 2020.05.24.20111864.

123 Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.

124 Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; : NEJMoa2016638.

125 Hopkinson NS, Rossi NN, Moustafa JE-SSE, et al. Current tobacco smoking and

risk from COVID-19 results from a population symptom app in over 2.4 million people. medrxiv 2020; 44: 2020.05.18.20105288.

126 Major home testing programme for coronavirus will track levels of infection in the community - GOV.UK. https://www.gov.uk/government/news/major-home-testingprogramme-for-coronavirus-will-track-levels-of-infection-in-the-community (accessed May 22, 2020).

Polubriaginof F, Salmasian H, Albert DA, Vawdrey DK. Challenges with Collecting
 Smoking Status in Electronic Health Records. AMIA . Annu Symp proceedings AMIA Symp
 2017; 2017: 1392–400.

128 Benowitz NL, Schultz KE, Haller CA, Wu AHB, Dains KM, Jacob P. Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol 2009; 170: 885–91.

129 Griffith G, Morris TT, Tudball M, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. medRxiv 2020; : 2020.05.04.20090506.

130 Murray E. Causation in smoking and COVID-19. Twitter. 2020. https://twitter.com/EpiEllie/status/1258607277357006849?s=20.

131 Bowyer RCE, Varsavsky T, Carole H. Geo-social gradients in predicted COVID-19 prevalence and severity in Great Britain : results from Affiliations : Corresponding authors : Understanding the geographical distribution of COVID-19 through the general population is key to the provision of ade. 2020.

132 Jackson SE, Brown J, Shahab L, Steptoe A, Fancourt D. COVID-19, smoking, and inequalities: a cross-sectional survey of adults in the UK. Submitted 2020.

133 Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: Rationale, and evidence for advantages over existing systems. CNS Drugs 2013; 27: 1007–19.

Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T.
Physician advice for smoking cessation. Cochrane Database Syst. Rev. 2013; 2017.
DOI:10.1002/14651858.CD000165.pub4.

Appendix 1

We used the following three criteria from the NIH National Heart, Lung and Blood Institute quality assessment tool for observational cohort and cross-sectional studies to assess study quality.

8: For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure

measured as continuous variable)?

9: Were the exposure measures (independent variables) clearly defined, valid, reliable and implemented consistently across all study participants?

14: Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

Lead Author	8.	9.	14.	Missing data	Overall rating (Poor, Fair, Good)	
Guan, Ni	Yes	Yes	No	1.27%	Fair	
Guan, Liang	No	No	Yes	0.00%	Poor	
Lian	No	No	No	93.15%	Poor	
Jin	No	No	No	93.70%	Poor	
Chen	No	No	No	93.07%	Poor	
Zhou, Yu	No	No	No	94.24%	Poor	
Mo	No	No	No	96.13%	Poor	
Zhang, Dong	No	No	No	93.57%	Poor	
Wan	No	No	No	93.33%	Poor	
Liu, Tao	No	No	No	93.59%	Poor	
Huang, Wang	No	No	No	92.68%	Poor	
Zhang, Cai	No	No	No	93.64%	Poor	
Guo	No	No	No	90.37%	Poor	
Liu, Ming	No	No	No	90.24%	Poor	
Huang, Yang	No	No	No	88.89%	Poor	
Xu	No	No	No	88.68%	Poor	
Li	No	No	No	82.35%	Poor	
Rentsch	Yes	Yes	Yes	5.30%	Fair	
Hu	No	No	Yes	88.24%	Poor	
Wang, Pan	No	No	No	87.20%	Poor	
Chow (US CDC)	No	No	No	96.36%	Poor	
Petrilli	No	No	Yes	0.00%	Poor	
Dong, Cao	No	No	No	88.89%	Poor	
Kim	No	No	No	82.14%	Poor	
Shi, Yu	No	No	No	91.79%	Poor	
Yang, Yu	No	No	No	96.15%	Poor	
Argenziano	Yes	Yes	No	0.00%	Fair	
Solis	No	No	No	90.62%	Poor	
Richardson	No	No	No	37.42%	Poor	
Fontanet	No	No	Yes	0.00%	Poor	
Zheng, Gao	No	No	No	87.88%	Poor	
Liao, Feng	No	No	No	99.57%	Poor	
Rodriguez	No	No	No	0.00%	Poor	
Magagnoli	No	No	No	85.87%	Poor	
Shi, Ren	No	No	No	89.55%	Poor	
Hadiadi	Yes	Yes	No	0.00%	Fair	
Niedzwiedz	Yes	Yes	Yes	0.59%	Fair	
Gold (US CDC)	No	No	No	94.75%	Poor	
Yu, Cai	No	No	No	91.58%	Poor	
Zheng, Xiong	No	No	No	0.00%	Poor	
Miyars	Yes	Yes	Yes	1.88%	Fair	
de la Rica	No	No	Yes	79.17%	Poor	
Yin, Yang	No	No	No	83.02%	Poor	
Gaibazzi	Yes	Yes	Yes	0.00%	Fair	
Shi, Zuo	No	No	No	69.79%	Poor	
Cho	Yes	Yes	Yes	0.00%	Fair	
Allenbach	No	No	No	93.42%	Poor	
Robilotti	Yes	Yes	No	1.65%	Fair	

The Opensafely Collaborative	Yes	Yes	Yes	4.18%	Fair
Borobia	No	No	No	92.95%	Poor
Giacomelli	No	No	No	0.00%	Poor
Shah	Yes	No	No	23.73%	Poor
Bello-Chavolla	No	No	No	90.06%	Poor
Kolin	Yes No	Yes No	No No	0.81% 77.78%	Fair Poor
Lubetzky		No			
Goyal	No		No	94.91%	Poor
Feng	No	No	No	90.76%	Poor
Yao Sami	No	No	No	96.30%	Poor
	No	No	No	0.00%	Poor
Almazeedi	No	No	Yes	0.00%	Poor
Carillo, Vega	No	No	No	0.00%	Poor
Yanover	Yes	Yes	No	0.00%	Fair
Hamer	Yes	Yes	Yes	0.00%	Fair
Regina	No	No	No	95.50%	Poor
de Lusignan	Yes	Yes	Yes	13.44%	Fair
Targher	No	No	No	91.74%	Poor
Valenti	No	No	No	74.14%	Poor
Feuth	Yes	Yes	No	0.00%	Fair
Heng	No	No	No	86.27%	Poor
Parrotta	Yes	Yes	No	2.63%	Fair
Shekhar	No	No	No	52.00%	Poor
Megia-Vilet	No	No	No	93.01%	Poor
Chen, Jiang	No	No	No	90.37%	Poor
Li, Chen	No	No	No	94.35%	Poor
Rimland	No	No	No	81.82%	Poor
Palaiodimos	No	No	No	0.00%	Poor
lp	Yes	Yes	No	14.61%	Fair
Heili-Frades	No	No	Yes	11.16%	Poor
Vaquero-Roncer	No	No	No	93.15%	Poor
Kim, Garg	No	No	Yes	0.08%	Poor
Wu	No	No	No	66.67%	Poor
Shi, Zhao	No	No	No	95.05%	Poor
Kimmig	No	No	No	63.33%	Poor
Al-Hindawi	Yes	Yes	No	0.00%	Fair
Basse	No	No	No	82.27%	Poor
Freites	No	No	Yes	98.75%	Poor
Alshami	No	No	No	82.03%	Poor
Russell	Yes	No	Yes	29.25%	Poor
Berumen	No	No	Yes	0.00%	Poor
Gianfrancesco	No	No	No	13.67%	Poor
Li, Long	No	No	No	94.48%	Poor
Batty	No	No	No	88.77%	Poor
Israel	Yes	Yes	Yes	0.00%	Fair
del Valle	Yes	No	Yes	71.16%	Poor
Zuo, Zuo	No	No	No	72.73%	Poor
Chaudhry	No	No	No	85.00%	Poor
Louis	No	No	No	54.55%	Poor
Soto-Mota	No	No	No	88.00%	Poor
	-				
Patel	No	No	No	9.62%	Poor
Garibaldi	No	No	No	71.88%	Poor
Docherty	Yes	No	Yes	29.55%	Poor
Boulware	NA	NA	NA	98.71%	NA